Evolus says the U.S. botulinum toxin market is stabilizing after the 2024 pullback, anticipating low-single-digit progress now with a return to mid-single-digit progress by 2027–2028.
Its new HA product, Evolysse, is gaining traction—now in about 3,000 U.S. clinics with constructive injector suggestions on effectivity, management and length, supported by hands-on coaching for over 12,000 injectors, and the flagship Sculpt formulation is anticipated to be authorized later this yr.
Administration raised its 2028 outlook to $450–$500 million in income with 13%–15% adjusted EBITDA, reiterated 2026 steerage of $327–$337 million, and is driving progress by way of Jeuveau+Evolysse bundling and worldwide growth.
Evolus (NASDAQ:EOLS) executives mentioned they’re seeing indicators of stabilization and enchancment within the U.S. botulinum toxin market after a interval of industry-wide stress, whereas describing a slower restoration for dermal fillers amid altering shopper sentiment. Talking on the Leerink Convention, CEO David Moatazedi, CFO Tatjana Mitchell, and Head of R&D Rui Avelar additionally outlined the corporate’s longer-term monetary targets and up to date industrial initiatives tied to its rising injectable portfolio.
Moatazedi mentioned the corporate feels “quite a bit higher” concerning the toxin market, citing enchancment starting within the fourth quarter and persevering with into the primary quarter. He framed final yr’s slowdown as notable as a result of, in his view, the aesthetics toxin class has solely skilled three intervals of unfavorable progress in roughly 25 years: the 2008–2009 recession, COVID shutdowns, and final yr’s pullback.
In response to Moatazedi, the 2024 downturn was pushed largely by a middle-class shopper decreasing discretionary spending amid increased prices and broader uncertainty. He mentioned the slowdown was not remoted to a specific age group or observe setting, describing it as widespread throughout channels. He added that, as in prior downturns, shoppers tended to stretch the intervals between therapies to increase the worth of every greenback.
Moatazedi mentioned the corporate’s present view aligns with low-single-digit market progress assumptions for toxins, with an inner expectation that the market may return to mid-single-digit progress in 2027 and 2028. He characterised Evolus’ stance as conservative versus historic rebounds, whereas noting that clinics and nationwide accounts have been signing up for progress and increasing their footprints.
Moatazedi mentioned the filler market has been slower to recuperate than toxins, attributing a number of the weak point—notably in hyaluronic acid (HA) fillers—to unfavorable sentiment round “overfilled” faces and a shopper desire for extra natural-looking outcomes. He described the filler softness as a two-year cycle and mentioned clinics have more and more been messaging each the protection of HA and its skill to ship pure outcomes.
He highlighted Evolus’ “Drop the F Phrase” marketing campaign tied to its Evolysse launch, which inspires clinics to keep away from the phrase “filler” in favor of “injectable HA.” Moatazedi mentioned he believes sentiment is starting to show in Europe, pointing to the U.Ok. as a market the place HA tendencies are bettering and doubtlessly serving as a lead indicator for the U.S., which he mentioned could also be a few yr behind.
On GLP-1 weight-loss medicine, Moatazedi mentioned aesthetic clinics are seeing and treating GLP-1 sufferers, however advised the impression will take time to circulate via as a result of sufferers want to succeed in desired weight, establish clinics, and price range for therapies. He additionally famous that declining GLP-1 pricing may assist alleviate some affordability constraints.
Avelar described Evolysse’s HA gel know-how as being manufactured at near-freezing temperatures to protect the pure HA construction. He mentioned suggestions throughout diligence and in observe has been constant in a number of areas:
Effectivity: injectors report needing much less product to attain correction.
Forgiveness: the gel can be utilized extra superficially with fewer points versus some sturdy gels.
Management: practitioners report the flexibility to inject to an supposed end result while not having to under- or over-correct.
Period: the corporate noticed good length in medical trials, which Avelar mentioned can also be resonating in observe.
Moatazedi mentioned Evolysse has carried out effectively regardless of broader filler class declines, stating the launch would rank amongst high HA launches given the market surroundings. He mentioned the product is at the moment in about 3,000 U.S. clinics and that Evolus plans a deliberate effort within the second quarter to increase adoption.
He additionally emphasised the corporate’s coaching infrastructure, saying Evolus carried out hands-on coaching for greater than 12,000 injectors final yr. Moatazedi mentioned the corporate has discovered {that a} second hands-on coaching session may be an inflection level in utilization as clinics acquire confidence with the product.
Moatazedi mentioned the corporate’s mixture of Evolysse and Jeuveau is strategically essential as a result of Evolus traditionally competed as a single-product firm. He described a bundling pilot within the fourth quarter that supplied incentives tied to incremental progress throughout each product strains; the corporate rolled out a broader six-month program nationally in January, designed to reflect loyalty-style packages supplied by bigger opponents.
In discussing aggressive dynamics, Moatazedi mentioned clinics might have restricted Jeuveau share resulting from portfolio economics with opponents, and that including fillers helps “unlock” share alternatives. He mentioned Evolus’ Jeuveau share throughout the clinics it serves is roughly 25%–30%, and he advised that share is capped extra by economics than by product efficiency. He additionally mentioned the expanded portfolio is enabling entry to bigger clinics that favor fewer vendor partnerships.
Trying forward, Moatazedi mentioned Evolus expects approval of Evolysse Sculpt later this yr, calling it the flagship product within the line and noting mid-face is a extra premium and technically difficult space. Mitchell added that Sculpt is anticipated to be the most important product in greenback income throughout the four-product filler line, doubtlessly round 40% or increased. Administration additionally referenced extra product circulate after Sculpt, together with “eyes subsequent yr” and “lips” thereafter.
Mitchell reiterated the corporate’s 2026 steerage of $327 million to $337 million in income, representing about 10% to 13% year-over-year progress. She mentioned Evolus is guiding to low- to mid-single-digit adjusted EBITDA margins in 2026, noting the corporate was worthwhile within the fourth quarter and expects to construct from there.
For 2028, Mitchell mentioned Evolus revised its long-term outlook to $450 million to $500 million in income with 13% to fifteen% adjusted EBITDA margins. She described progress drivers throughout:
Jeuveau: at the moment at 14% U.S. share, with steerage assuming a transfer into the mid-teens.
Evolysse: anticipated to be 10%–12% of world income in 2026, with solely two merchandise (Type and Clean) contributing at the moment.
Worldwide growth: worldwide income practically doubled in 2025 and moved from 5% to eight% of whole income; the corporate expects worldwide to succeed in about 15% of income by 2028.
Mitchell mentioned the corporate “rebased” bills in 2025 because it constructed industrial infrastructure for the filler launch, and she or he expects working leverage going ahead with out a comparable step-up in working expense. Moatazedi additionally highlighted Evolus’ shopper loyalty program, which he mentioned has grown to greater than 1.4 million shoppers and is co-branded with clinics, together with automated reminders and credit designed to deliver sufferers again to the identical observe.
Internationally, administration mentioned Evolus has a direct presence within the U.Ok., Germany, Spain, and Italy, with France served via accomplice Symatese; additionally it is direct in Australia and partnered in Canada. Moatazedi mentioned the European toxin market has continued to develop at mid-single digits and that worldwide markets didn’t expertise the identical financial stress seen within the U.S. He estimated that the markets by which Evolus operates symbolize near a $2 billion alternative exterior the U.S. throughout toxin and filler, and that the corporate’s mixed share throughout these markets stays within the low single digits.
Evolus, Inc is a specialty pharmaceutical firm targeted on medical aesthetics. Headquartered in Newport Seashore, California, Evolus develops and commercializes merchandise designed to boost facial look via minimally invasive procedures. Since its founding in 2017, the corporate has positioned itself within the fast-growing aesthetic market by partnering with main producers and leveraging medical experience to deliver progressive injectables to practitioners and sufferers.
The corporate’s flagship providing, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator authorized by the U.S.
